Use of asenapine in clinical practice for the management of bipolar mania

Journal of Psychopharmacology

Volumn 27, Issue , 2013, Pages 3-13

  Young, Allan H ^a   Altamura, Alfredo Carlo ^b,c   González Pinto, Ana M ^d,e,f   Millet, Bruno ^g,h   Wiedemann, Klaus ⁱ  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Department of Psychiatry   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^f Kronikgune   (Spain)

^g UNIVERSITÉ DE RENNES 1   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

antimanic efficacy; Asenapine; atypical antipsychotic; bipolar disorder; bipolar mania; depressive symptoms; mixed episode

Indexed keywords

ASENAPINE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; BIPOLAR DISORDER; CASE REPORT; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84886432739     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786813482534     Document Type: Article

References (67)

1. Altamura AC Dell’Osso B Berlin HA. (2010) Duration of untreated illness and suicide in bipolar disorder: A naturalistic study. Eur Arch Psychiatry Clin Neurosci 260: 385–391.
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision (DSM-IV-TR). Washington DC: American Psychiatric Press.
3. American Psychiatric Association (2012) Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). DSM-5 Development. Available at: http://www.dsm5.org/Pages/Default.aspx (accessed 6 February 2013).
4. Angst J Sellaro R (2000) Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 48: 445–457.
5. Azorin JM Sapin C Weiller E (2013) Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: Results from post hoc analyses. J Affect Disord 145: 62–69.
6. Cazorla P Zhao J Szegedi A (2012a) Incidence, onset and duration of treatment-emergent somnolence with asenapine in patients with schizophrenia or bipolar disorder. Poster presented at the 20th European Congress of Psychiatry, 3–6 March 2012, Prague, Czech Republic.
7. Cazorla P Mackle M Zhao J (2012b) Safety and tolerability of switching to asenapine from other antipsychotic agents: Pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat 8: 247–257.
8. Chengappa KN Hennen J Baldessarini RJ (2005) Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord 7: 68–76.
9. Cookson J Hodgson R Wildgust HJ (2012) Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol 26: S42–S51.
10. Craig TJ Ye Q Bromet EJ (2006) Mortality among first-admission patients with psychosis. Compr Psychiatry 47: 246–251.
11. Dean BB Gerner D Gerner RH (2004) A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 20: 139–154.
12. Derry S Moore RA (2007) Atypical antipsychotics in bipolar disorder: Systematic review of randomised trials. BMC Psychiatry 7: 40.
13. Dratcu L Bobmanuel S Davies W (2012) A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania. Int J Psychiatry Clin Pract 16: 244–258.
14. Ertugrul A Meltzer HY (2003) Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 6: 277–284.
15. European Medicines Agency (2010) Committee for Medicinal Products for Human Use (CHMP) assessment report for Sycrest®. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001177/human_med_001379.jsp&mid=WC0b01ac058001d124 (accessed 6 February 2013).
16. Fountoulakis KN Vieta E (2008) Treatment of bipolar disorder: A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 11: 999–1029.
17. González-Pinto A Aldama A Mosquera F (2007) Epidemiology, diagnosis and management of mixed mania. CNS Drugs 21: 611–626.
18. González-Pinto A Barbeito S Alonso M. (2011) Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. J Clin Psychiatry 72: 671–676.
19. Goodwin GM; Consensus Group of the British Association for Psychopharmacology (2009). Evidence-based guidelines for treating bipolar disorder: Revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23: 346–388.
20. Grande I Goikolea JM de Dios C; for the PREBIS group (2012) Occupational disability in bipolar disorder: Analysis of predictors of being on severe disablement benefit (PREBIS study data). Acta Psychiatr Scand DOI: 10.1111/acps.12003.
21. Grunze H Vieta E Goodwin GM. (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry 10: 85–116.
22. Gutiérrez-Rojas L Jurado D Martínez-Ortega JM. (2010) Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 127: 77–83.
23. Hanssens L L’Italien G Loze JY. (2008) The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 8: 95.
24. Haro JM Reed C Gonzalez-Pinto A EMBLEM Advisory Board (2011) 2-year course of bipolar disorder type I patients in outpatient care: Factors associated with remission and functional recovery. Eur Neuropsychopharmacol 21: 287–293.
25. Harvey PW Everett DJ Springall CJ (2008) Adverse effects of prolactin in rodents and humans: Breast and prostate cancer. J Psychopharmacol 22: S20–S27.
26. Henderson DC (2007) Weight gain with atypical antipsychotics: Evidence and insights. J Clin Psychiatry 68: S18–S26.
27. Judd LL Akiskal HS Schettler PJ. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59: 530–537.
28. Kane JM Sharif ZA (2008) Atypical antipsychotics: Sedation versus efficacy. J Clin Psychiatry 69: S18–S31.
29. Khalsa HM Salvatore P Hennen J. (2008) Suicidal events and accidents in 216 first-episode bipolar I disorder patients: Predictive factors. J Affect Disord 106: 179–184.
30. Kleinman L Lowin A Flood E (2003) Costs of bipolar disorder. Pharmacoeconomics 21: 601–622.
31. Laaksonen DE Lakka HM Niskanen LK. (2002) Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156: 1070–1077.
32. Lakka HM Laaksonen DE Lakka TA. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709–2716.
33. Laxman KE Lovibond KS Hassan MK (2008) Impact of bipolar disorder in employed populations. Am J Manag Care 14: 757–764.
34. Lingam R Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105: 164–172.
35. Llorca PM Courtet P Martin P. (2010a) Screening and management of bipolar disorders: methodology. Encephale 36: S79–S85.
36. Llorca PM Courtet P Martin P; l’Association Française de Psychiatrie Biologique et Neuropsychopharmacologique (AFPBN) (2010b) Screening and management of bipolar disorders: results. Encephale 36: S86–S102.
37. McIntyre RS (2011) Long-term treatment of bipolar disorder in adults. J Clin Psychiatry 72: e06.
38. McIntyre RS Cohen M Zhao J. (2009a) A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 11: 673–686.
39. McIntyre RS Cohen M Zhao J (2009b) Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 11: 815–826.
40. McIntyre RS Cohen M Zhao J. (2010a) Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 122: 27–38.
41. McIntyre RS Cohen M Zhao J. (2010b) Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 126: 358–365.
42. Montejo AL (2008) Prolactin awareness: An essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 18: S108–S114.
43. National Institute for Health and Clinical Excellence (NICE) (2006) Clinical Guidance 38. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Available at: http://www.nice.org.uk/CG38 (accessed 6 February 2013).
44. Nemeroff CB (2003) Safety of available agents used to treat bipolar disorder: Focus on weight gain. J Clin Psychiatry 64: 532–539.
45. Newcomer JW Haupt DW (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 51: 480–491.
46. Nutt DJ (1994) Putting the ‘A’ in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol 8: 193–195.
47. O’Keane V (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 22: S70–S75.
48. Osman OT Rudorfer MV Potter WZ (1989) Idazoxan: A selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry 46: 958–959.
49. Perry A Tarrier N Morriss R (1999) Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 318: 149–153.
50. Sajatovic M Davies M Hrouda DR (2004) Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 55: 264–269.
51. Sanchez-Moreno J Martinez-Aran A Tabarés-Seisdedos R. (2009) Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 78: 285–297.
52. Saphris® Prescribing Information (2012) Available at US Food & Drug Administration website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed 6 February 2013).
53. Sapin C Corson H Hansen K (2011) The effect of asenapine on health-related quality of life in patients with manic or mixed episodes associated with bipolar I disorder. Poster presented at the 2nd International Congress on Neurobiology, Psychopharmacology & Treatment Guidance, 24–27 November 2011, Thessaloniki, Greece.
54. Shahid M Walker GB Zorn SH. (2009) Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23: 65–73.
55. Smith SM O’Keane V Murray R (2002) Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 181: 49–55.
56. Sycrest® Summary of Product Characteristics. (2012) Available at European Medicines Agency website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001177/human_med_001379.jsp&mid=WC0b01ac058001d124 (accessed 6 February 2013).
57. Szarfman A Tonning JM Levine JG. (2006) Atypical antipsychotics and pituitary tumors: A pharmacovigilance study. Pharmacotherapy 26: 748–758.
58. Szegedi A Calabrese JR Stet L Apollo Study Group (2012) Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 32: 46–55.
59. Szegedi A Zhao J van Willigenburg A (2011) Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC Psychiatry 11: 101.
60. Tohen M Vieta E Gonzalez-Pinto A.; European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Advisory Board (2010) Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry 71: 255–261.
61. Tohen M Zarate CA Hennen J (2003) The McLean-Harvard First-Episode Mania Study: Prediction of recovery and first recurrence. Am J Psychiatry 160: 2099–2107.
62. Torrent C Amann B Sánchez-Moreno J (2008) Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta Psychiatr Scand 118: 4–18.
63. Valentí M Pacchiarotti I Rosa AR (2011) Bipolar mixed episodes and antidepressants: A cohort study of bipolar I disorder patients. Bipolar Disord 13: 145–154.
64. Velligan DI Weiden PJ Sajatovic M Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness (2009) The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70: S1–S46.
65. Vieta E Morralla C (2010) Prevalence of mixed mania using 3 definitions. J Affect Disord 125: 61–73.
66. Yatham LN Kennedy SH Parikh SV (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 15: 1–44.
67. Zhao J Ha X Szegedi A (2011) Early improvement predicts later outcome in manic or mixed episodes associated with bipolar I disorder: Post hoc analyses. Poster presented at 164th Annual Meeting of the American Psychiatric Association, 14–18 May, 2011, Honolulu, Hawaii, USA.